A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Name: A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Published: 2026
License: Public Domain

GV20 Therapeutics · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

carcinoma cholangiocarcinoma colorectal-neoplasms esophageal-squamous-cell-carcinoma pancreatic-ductal-adenocarcinoma uterine-cervical-neoplasms

uterine cervical neoplasms, triple negative breast neoplasms, prostatic neoplasms, squamous cell carcinoma of head and neck, esophageal squamous cell carcinoma, cholangiocarcinoma, gallbladder neoplasms, colorectal neoplasms, pancreatic ductal adenocarcinoma, carcinoma, non-small-cell lung, small cell lung carcinoma, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Related documents